Shares of RPG Life Sciences remained in focus on Thursday after the company announced a major restructuring of its API business and brought private equity investor InvAscent on board.

The stock opened at Rs 2,863.40 on the NSE and touched an intraday high of Rs 2,899.80 as investors assessed the move and its potential to strengthen the company’s pharmaceutical manufacturing operations.

Under the plan, RPG Life Sciences will transfer its active pharmaceutical ingredients, or API, business to a new wholly owned subsidiary called RPG Active Pharma Ltd (RPGAP). InvAscent will invest up to Rs 243 crore for a roughly 40% stake in the new company.

The partnership is intended to give the API business greater access to capital and a sharper focus on expansion. RPG Life Sciences and InvAscent could together invest up to Rs 700 crore in RPGAP over time, with the funds expected to support manufacturing capacity, product development and other growth plans.

The restructuring comes as RPG Life Sciences looks to build a larger presence in the API market. Its API business generated Rs 95.06 crore in FY26, contributing around 13.5% of consolidated revenue.

The company said the new structure would help it respond to changing global pharmaceutical supply chains and growing demand for Indian API manufacturing.

RPG Active Pharma has also agreed to acquire Actis Generics Pvt Ltd, a Visakhapatnam-based API manufacturer, for Rs 80 crore in an all-cash transaction. Actis Generics reported revenue of Rs 48.2 crore in FY25, and the acquisition is expected to expand RPG’s manufacturing footprint and product portfolio.

At around 11:46 am, RPG Life Sciences shares were trading at Rs 2,824.30 on the NSE, down about 0.90% from the previous close, after moving within a day’s range of Rs 2,770 to Rs 2,899.80.

The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!